Biocompounding
Generics vs. Biosimilars: Why They're Not the Same Business
Generics and biosimilars have the same goal: cheaper versions of drugs whose patents have expired. That is where the similarity ends.
A generic is a commodity. It copies a small-molecule drug made by simple chemistry, and the copy is identical to the original. Because anyone can make it, many
Edwards Lifesciences (EW) — From Valve Pioneer to Structural Heart Powerhouse
1. The Premise
Today we are going to be looking at a company whose entire existence is concentrated on solving one disease, in one organ, for one population of patients — and which has spent six decades doing so with such singular intensity that it has become genuinely irreplaceable. Edwards Lifesciences
Intuitive Surgical (ISRG): What Three Years and a New Robot Changed
A Note to Readers
When we first wrote about Intuitive Surgical, the company was the unambiguous, effectively unchallenged leader of a market it had created. The investment thesis was compelling but simple: a dominant installed base, an annuity stream of instruments and service revenue, and a regulatory and switching-cost
Stryker Corporation (SYK): Engineering the Future of Healthcare
1. The Premise: A MedTech Compounder with Two Compounding Engines
The medtech industry is undergoing a structural transformation unlike any in its history. Three forces are converging simultaneously: the most powerful demographic tailwind in recorded medicine — an ageing global population whose joint, cardiovascular, and neurological needs are growing faster than
Veeva Systems: The Digital Nervous System of Global Biopharma
1. The Premise: The Architect of Life Sciences Digitalization
The global life sciences industry is currently navigating a period of profound structural transformation, driven by the convergence of heightened regulatory scrutiny, the explosion of clinical data volumes, and the imperative for operational efficiency in drug development. Within this landscape, Veeva
Medtronic Deep Dive - The Awakening of a Sleeping Giant: Medtronic’s Strategic Pivot to Innovation-Driven Growth
I. The Premise: Assessing the Sleeping Giant
1.1. Introduction: Validating the "Awakening" Thesis
The term "Sleeping Giant" has historically applied to Medtronic plc (NYSE: MDT) due to its immense market capitalization, global footprint, and foundational role in health technology, often contrasted with periods of slower